Review



ivis spectrum system  (Revvity)


Bioz Verified Symbol Revvity is a verified supplier
Bioz Manufacturer Symbol Revvity manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Revvity ivis spectrum system
    CD169+ macrophages repress tumor progression in liver. (A-D) B16-F10 melanoma cells grew faster in CD169-DTR mice. (A) Experimental design. (B) Growth of tumors was examined using in vivo imaging system by evaluating abdominal fluorescence signals. The average radiance of two groups were compared. Two-way ANOVA with Sidak's multiple comparisons test. (C) The livers bearing with metastatic tumors were harvested (left panel). The number of tumors in each liver were counted (right panel). (D) Representative H&E staining of liver tissues. Scale bar, 200μm, 50μm. The data were from one experiment representative of two independent experiments. (E-G) Transfer of CD169+ macrophages inhibits B16-F10 melanoma cells growth in CD169-DTR mice. (E) Experiment design (n = 3∼4 per group). (F) The abdominal fluorescence signals were examined with in vivo imaging system. The average radiance of two groups were compared. (G) The livers were harvested from the mice receiving CD169+ macrophages or vehicle, and number of tumors were counted.
    Ivis Spectrum System, supplied by Revvity, used in various techniques. Bioz Stars score: 96/100, based on 38454 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/execution+platform/IVIS+optical+imaging+platform/pmc08662336-57-25-28
    Average 96 stars, based on 38454 article reviews
    ivis spectrum system - by Bioz Stars, 2026-11
    96/100 stars

    Images

    1) Product Images from "CD169-positive macrophages enhance abscopal effect of radiofrequency ablation therapy in liver cancer"

    Article Title: CD169-positive macrophages enhance abscopal effect of radiofrequency ablation therapy in liver cancer

    Journal: Translational Oncology

    doi: 10.1016/j.tranon.2021.101306

    CD169+ macrophages repress tumor progression in liver. (A-D) B16-F10 melanoma cells grew faster in CD169-DTR mice. (A) Experimental design. (B) Growth of tumors was examined using in vivo imaging system by evaluating abdominal fluorescence signals. The average radiance of two groups were compared. Two-way ANOVA with Sidak's multiple comparisons test. (C) The livers bearing with metastatic tumors were harvested (left panel). The number of tumors in each liver were counted (right panel). (D) Representative H&E staining of liver tissues. Scale bar, 200μm, 50μm. The data were from one experiment representative of two independent experiments. (E-G) Transfer of CD169+ macrophages inhibits B16-F10 melanoma cells growth in CD169-DTR mice. (E) Experiment design (n = 3∼4 per group). (F) The abdominal fluorescence signals were examined with in vivo imaging system. The average radiance of two groups were compared. (G) The livers were harvested from the mice receiving CD169+ macrophages or vehicle, and number of tumors were counted.
    Figure Legend Snippet: CD169+ macrophages repress tumor progression in liver. (A-D) B16-F10 melanoma cells grew faster in CD169-DTR mice. (A) Experimental design. (B) Growth of tumors was examined using in vivo imaging system by evaluating abdominal fluorescence signals. The average radiance of two groups were compared. Two-way ANOVA with Sidak's multiple comparisons test. (C) The livers bearing with metastatic tumors were harvested (left panel). The number of tumors in each liver were counted (right panel). (D) Representative H&E staining of liver tissues. Scale bar, 200μm, 50μm. The data were from one experiment representative of two independent experiments. (E-G) Transfer of CD169+ macrophages inhibits B16-F10 melanoma cells growth in CD169-DTR mice. (E) Experiment design (n = 3∼4 per group). (F) The abdominal fluorescence signals were examined with in vivo imaging system. The average radiance of two groups were compared. (G) The livers were harvested from the mice receiving CD169+ macrophages or vehicle, and number of tumors were counted.

    Techniques Used: In Vivo Imaging, Fluorescence, Staining

    Related Articles

    Mouse Assay:

    Article Title: A user-friendly strategy to engineer tailored intermediate strains for overcoming combined type I and type II restriction-modification barriers in Staphylococcus aureus
    Article Snippet: se receiving only the substrate served as the negative control. Three minutes after substrate injection, bioluminescence signals from the kidneys were detected on the dorsal side of the mouse using an IVIS Lumina LT imaging system. The preparation of the HFZ substrate and the image acquisition parameters were based on a previous study [ 18 ]. Ethical approval Female BALB/c mice (6–8 weeks old, 16–2

    Control:

    Article Title: A user-friendly strategy to engineer tailored intermediate strains for overcoming combined type I and type II restriction-modification barriers in Staphylococcus aureus
    Article Snippet: se receiving only the substrate served as the negative control. Three minutes after substrate injection, bioluminescence signals from the kidneys were detected on the dorsal side of the mouse using an IVIS Lumina LT imaging system. The preparation of the HFZ substrate and the image acquisition parameters were based on a previous study [ 18 ]. Ethical approval Female BALB/c mice (6–8 weeks old, 16–2

    Imaging:

    Article Title: A user-friendly strategy to engineer tailored intermediate strains for overcoming combined type I and type II restriction-modification barriers in Staphylococcus aureus
    Article Snippet: se receiving only the substrate served as the negative control. Three minutes after substrate injection, bioluminescence signals from the kidneys were detected on the dorsal side of the mouse using an IVIS Lumina LT imaging system. The preparation of the HFZ substrate and the image acquisition parameters were based on a previous study [ 18 ]. Ethical approval Female BALB/c mice (6–8 weeks old, 16–2

    Injection:

    Article Title: A user-friendly strategy to engineer tailored intermediate strains for overcoming combined type I and type II restriction-modification barriers in Staphylococcus aureus
    Article Snippet: se receiving only the substrate served as the negative control. Three minutes after substrate injection, bioluminescence signals from the kidneys were detected on the dorsal side of the mouse using an IVIS Lumina LT imaging system. The preparation of the HFZ substrate and the image acquisition parameters were based on a previous study [ 18 ]. Ethical approval Female BALB/c mice (6–8 weeks old, 16–2

    Negative Control:

    Article Title: A user-friendly strategy to engineer tailored intermediate strains for overcoming combined type I and type II restriction-modification barriers in Staphylococcus aureus
    Article Snippet: se receiving only the substrate served as the negative control. Three minutes after substrate injection, bioluminescence signals from the kidneys were detected on the dorsal side of the mouse using an IVIS Lumina LT imaging system. The preparation of the HFZ substrate and the image acquisition parameters were based on a previous study [ 18 ]. Ethical approval Female BALB/c mice (6–8 weeks old, 16–2

    Concentration Assay:

    Article Title: A user-friendly strategy to engineer tailored intermediate strains for overcoming combined type I and type II restriction-modification barriers in Staphylococcus aureus
    Article Snippet: se receiving only the substrate served as the negative control. Three minutes after substrate injection, bioluminescence signals from the kidneys were detected on the dorsal side of the mouse using an IVIS Lumina LT imaging system. The preparation of the HFZ substrate and the image acquisition parameters were based on a previous study [ 18 ]. Ethical approval Female BALB/c mice (6–8 weeks old, 16–2

    Migration:

    Article Title: A user-friendly strategy to engineer tailored intermediate strains for overcoming combined type I and type II restriction-modification barriers in Staphylococcus aureus
    Article Snippet: se receiving only the substrate served as the negative control. Three minutes after substrate injection, bioluminescence signals from the kidneys were detected on the dorsal side of the mouse using an IVIS Lumina LT imaging system. The preparation of the HFZ substrate and the image acquisition parameters were based on a previous study [ 18 ]. Ethical approval Female BALB/c mice (6–8 weeks old, 16–2

    In Vitro:

    Article Title: A user-friendly strategy to engineer tailored intermediate strains for overcoming combined type I and type II restriction-modification barriers in Staphylococcus aureus
    Article Snippet: se receiving only the substrate served as the negative control. Three minutes after substrate injection, bioluminescence signals from the kidneys were detected on the dorsal side of the mouse using an IVIS Lumina LT imaging system. The preparation of the HFZ substrate and the image acquisition parameters were based on a previous study [ 18 ]. Ethical approval Female BALB/c mice (6–8 weeks old, 16–2

    Fluorescence:

    Article Title: A user-friendly strategy to engineer tailored intermediate strains for overcoming combined type I and type II restriction-modification barriers in Staphylococcus aureus
    Article Snippet: se receiving only the substrate served as the negative control. Three minutes after substrate injection, bioluminescence signals from the kidneys were detected on the dorsal side of the mouse using an IVIS Lumina LT imaging system. The preparation of the HFZ substrate and the image acquisition parameters were based on a previous study [ 18 ]. Ethical approval Female BALB/c mice (6–8 weeks old, 16–2

    In Vivo:

    Article Title: A user-friendly strategy to engineer tailored intermediate strains for overcoming combined type I and type II restriction-modification barriers in Staphylococcus aureus
    Article Snippet: se receiving only the substrate served as the negative control. Three minutes after substrate injection, bioluminescence signals from the kidneys were detected on the dorsal side of the mouse using an IVIS Lumina LT imaging system. The preparation of the HFZ substrate and the image acquisition parameters were based on a previous study [ 18 ]. Ethical approval Female BALB/c mice (6–8 weeks old, 16–2

    Oligomer Restriction:

    Article Title: A user-friendly strategy to engineer tailored intermediate strains for overcoming combined type I and type II restriction-modification barriers in Staphylococcus aureus
    Article Snippet: se receiving only the substrate served as the negative control. Three minutes after substrate injection, bioluminescence signals from the kidneys were detected on the dorsal side of the mouse using an IVIS Lumina LT imaging system. The preparation of the HFZ substrate and the image acquisition parameters were based on a previous study [ 18 ]. Ethical approval Female BALB/c mice (6–8 weeks old, 16–2

    Analysis:

    Article Title: A user-friendly strategy to engineer tailored intermediate strains for overcoming combined type I and type II restriction-modification barriers in Staphylococcus aureus
    Article Snippet: se receiving only the substrate served as the negative control. Three minutes after substrate injection, bioluminescence signals from the kidneys were detected on the dorsal side of the mouse using an IVIS Lumina LT imaging system. The preparation of the HFZ substrate and the image acquisition parameters were based on a previous study [ 18 ]. Ethical approval Female BALB/c mice (6–8 weeks old, 16–2

    In Vivo Imaging:

    Article Title: A user-friendly strategy to engineer tailored intermediate strains for overcoming combined type I and type II restriction-modification barriers in Staphylococcus aureus
    Article Snippet: se receiving only the substrate served as the negative control. Three minutes after substrate injection, bioluminescence signals from the kidneys were detected on the dorsal side of the mouse using an IVIS Lumina LT imaging system. The preparation of the HFZ substrate and the image acquisition parameters were based on a previous study [ 18 ]. Ethical approval Female BALB/c mice (6–8 weeks old, 16–2

    Software:

    Article Title: A user-friendly strategy to engineer tailored intermediate strains for overcoming combined type I and type II restriction-modification barriers in Staphylococcus aureus
    Article Snippet: se receiving only the substrate served as the negative control. Three minutes after substrate injection, bioluminescence signals from the kidneys were detected on the dorsal side of the mouse using an IVIS Lumina LT imaging system. The preparation of the HFZ substrate and the image acquisition parameters were based on a previous study [ 18 ]. Ethical approval Female BALB/c mice (6–8 weeks old, 16–2

    Ex Vivo:

    Article Title: A user-friendly strategy to engineer tailored intermediate strains for overcoming combined type I and type II restriction-modification barriers in Staphylococcus aureus
    Article Snippet: se receiving only the substrate served as the negative control. Three minutes after substrate injection, bioluminescence signals from the kidneys were detected on the dorsal side of the mouse using an IVIS Lumina LT imaging system. The preparation of the HFZ substrate and the image acquisition parameters were based on a previous study [ 18 ]. Ethical approval Female BALB/c mice (6–8 weeks old, 16–2

    Labeling:

    Article Title: A user-friendly strategy to engineer tailored intermediate strains for overcoming combined type I and type II restriction-modification barriers in Staphylococcus aureus
    Article Snippet: se receiving only the substrate served as the negative control. Three minutes after substrate injection, bioluminescence signals from the kidneys were detected on the dorsal side of the mouse using an IVIS Lumina LT imaging system. The preparation of the HFZ substrate and the image acquisition parameters were based on a previous study [ 18 ]. Ethical approval Female BALB/c mice (6–8 weeks old, 16–2

    Suspension:

    Article Title: A user-friendly strategy to engineer tailored intermediate strains for overcoming combined type I and type II restriction-modification barriers in Staphylococcus aureus
    Article Snippet: se receiving only the substrate served as the negative control. Three minutes after substrate injection, bioluminescence signals from the kidneys were detected on the dorsal side of the mouse using an IVIS Lumina LT imaging system. The preparation of the HFZ substrate and the image acquisition parameters were based on a previous study [ 18 ]. Ethical approval Female BALB/c mice (6–8 weeks old, 16–2



    Similar Products

    execution platform  (MathWorks Inc)
    96
    MathWorks Inc execution platform
    Execution Platform, supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/execution+platform/Simulink+Real-Time/10__1016_slash_j__rineng__2024__102416-184-19-23
    Average 96 stars, based on 1 article reviews
    execution platform - by Bioz Stars, 2026-11
    96/100 stars
    		  Buy from Supplier
    cpal execution platform  (MathWorks Inc)
    90
    MathWorks Inc cpal execution platform
    Controller model for an inverted pendulum integrated within <t>the</t> <t>Simulink</t> environment. Input data of the controller are visible in the design window and can be changed without the need to access the <t>CPAL</t> model. The output data are updated by the CPAL controler. The controller model is written in CPAL and executed by an interpreter embedded in the controller block. The ast file format is the more-compact binary equivalent form of the source-code controller model.
    Cpal Execution Platform, supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/execution+platform/pmc05856116-69-3-7
    Average 90 stars, based on 1 article reviews
    cpal execution platform - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    syngo ‡ execution platform  (Siemens Healthineers)
    90
    Siemens Healthineers syngo ‡ execution platform
    Controller model for an inverted pendulum integrated within <t>the</t> <t>Simulink</t> environment. Input data of the controller are visible in the design window and can be changed without the need to access the <t>CPAL</t> model. The output data are updated by the CPAL controler. The controller model is written in CPAL and executed by an interpreter embedded in the controller block. The ast file format is the more-compact binary equivalent form of the source-code controller model.
    Syngo ‡ Execution Platform, supplied by Siemens Healthineers, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/execution+platform/syngo+%E2%80%A1+execution+platform/10__1002_slash_spe__613-61-8-17
    Average 90 stars, based on 1 article reviews
    syngo ‡ execution platform - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Controller model for an inverted pendulum integrated within the Simulink environment. Input data of the controller are visible in the design window and can be changed without the need to access the CPAL model. The output data are updated by the CPAL controler. The controller model is written in CPAL and executed by an interpreter embedded in the controller block. The ast file format is the more-compact binary equivalent form of the source-code controller model.

    Journal: Sensors (Basel, Switzerland)

    Article Title: A Model-Driven Co-Design Framework for Fusing Control and Scheduling Viewpoints

    doi: 10.3390/s18020628

    Figure Lengend Snippet: Controller model for an inverted pendulum integrated within the Simulink environment. Input data of the controller are visible in the design window and can be changed without the need to access the CPAL model. The output data are updated by the CPAL controler. The controller model is written in CPAL and executed by an interpreter embedded in the controller block. The ast file format is the more-compact binary equivalent form of the source-code controller model.

    Article Snippet: We provide the CPAL execution platform for Simulink as open access for experimentation.

    Techniques: Blocking Assay

    Illustration of a CPAL controller in Simulink. Here, the CPAL model controls the servo which in turn actuates the engine throttle. The controller task is executed with simulated input-to-output delays.

    Journal: Sensors (Basel, Switzerland)

    Article Title: A Model-Driven Co-Design Framework for Fusing Control and Scheduling Viewpoints

    doi: 10.3390/s18020628

    Figure Lengend Snippet: Illustration of a CPAL controller in Simulink. Here, the CPAL model controls the servo which in turn actuates the engine throttle. The controller task is executed with simulated input-to-output delays.

    Article Snippet: We provide the CPAL execution platform for Simulink as open access for experimentation.

    Techniques: